Platelet-mediated hemostasis depends on adhesion and aggregation, principally mediated by the glycoprotein IIb/IIIa surface molecule, which binds collagen at sites of tissue damage and cross-links platelets via fibrinogen, alongside a release function driven by thromboxane A2 and ATP. Antiplatelet drug classes act at distinct points in this pathway: irreversible cyclooxygenase inhibition (blocking thromboxane A2 synthesis), direct glycoprotein IIb/IIIa receptor inhibition, ADP receptor inhibition (reversible or irreversible), and phosphodiesterase inhibition combined with adenosine reuptake inhibition (raising cyclic AMP, which itself suppresses aggregation). This content belongs to pharmacology, specifically the pharmacology of hemostasis and thrombosis, and demonstrates how differing molecular targets within the platelet activation pathway produce differing clinical efficacy, duration of action, reversibility, and toxicity profiles.
Platelet-mediated hemostasis depends on adhesion and aggregation, principally mediated by the glycoprotein IIb/IIIa surface molecule, which binds collagen at sites of tissue damage and cross-links pl…